Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

NCT04318717 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Mucosal Melanoma of the Head and Neck

Interventions

DRUG: Pembrolizumab
RADIATION: Hypofractionated radiation therapy

Sponsor

Washington University School of Medicine